AR116876A1 - Vacuna de ibv 4/91 con proteína espicular heteróloga - Google Patents

Vacuna de ibv 4/91 con proteína espicular heteróloga

Info

Publication number
AR116876A1
AR116876A1 ARP190103113A ARP190103113A AR116876A1 AR 116876 A1 AR116876 A1 AR 116876A1 AR P190103113 A ARP190103113 A AR P190103113A AR P190103113 A ARP190103113 A AR P190103113A AR 116876 A1 AR116876 A1 AR 116876A1
Authority
AR
Argentina
Prior art keywords
ibv
protein
spicular
heterological
vaccine
Prior art date
Application number
ARP190103113A
Other languages
English (en)
Inventor
Hans Philipp
- Kraemer-Kuehl Annika Christian
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR116876A1 publication Critical patent/AR116876A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reivindicación 7: El IBV o la composición inmunógena de acuerdo con cualquiera de las reivindicaciones 1 a 6, caracterizado porque la proteína S heteróloga es la proteína espicular de longitud completa, o en donde el fragmento de la proteína S (espicular) heteróloga tiene una longitud de al menos 500, 750, 1000 ó 1075 aminoácidos. Reivindicación 8: El IBV o la composición inmunógena de acuerdo con cualquiera de las reivindicaciones 1 a 7, caracterizado porque el IBV está atenuado o el IBV es un IBV recombinante.
ARP190103113A 2018-10-31 2019-10-28 Vacuna de ibv 4/91 con proteína espicular heteróloga AR116876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18203626 2018-10-31

Publications (1)

Publication Number Publication Date
AR116876A1 true AR116876A1 (es) 2021-06-23

Family

ID=64048879

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103113A AR116876A1 (es) 2018-10-31 2019-10-28 Vacuna de ibv 4/91 con proteína espicular heteróloga

Country Status (12)

Country Link
US (2) US11224649B2 (es)
EP (1) EP3873516A1 (es)
JP (1) JP7206383B2 (es)
KR (1) KR20210087058A (es)
CN (1) CN112996537A (es)
AR (1) AR116876A1 (es)
BR (1) BR112021008440A2 (es)
CO (1) CO2021005066A2 (es)
EA (1) EA202191145A1 (es)
IL (1) IL282465A (es)
MX (1) MX2021004907A (es)
WO (1) WO2020089164A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3965812A1 (en) 2019-05-10 2022-03-16 Boehringer Ingelheim Vetmedica GmbH Modified s1 subunit of the coronavirus spike protein
AU2021378483A1 (en) * 2020-11-12 2023-06-08 Intervet International B.V. Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
DK0639640T3 (da) * 1993-07-30 2001-01-02 Akzo Nobel Nv Fjerkrævaccine indeholdende smitsomt bronchitis-virus serotype 4/91
EP1196552A2 (en) * 1999-06-25 2002-04-17 Maxygen, Inc. Methods and compositions for engineering of attenuated vaccines
IL151039A0 (en) 2000-02-29 2003-04-10 Wyeth Corp In ovo protection against infectious bronchitis
WO2004078203A2 (en) 2003-03-03 2004-09-16 Akzo Nobel N.V. Infectious bronchitis virus with an altered spike gene
CN1917900A (zh) * 2003-10-30 2007-02-21 勃林格殷格翰动物保健有限公司 猪红斑丹毒丝菌－副猪嗜血菌疫苗及其使用方法
US8679504B2 (en) * 2008-05-22 2014-03-25 University Of Georgia Research Foundation Inc. Poultry viral materials and methods related thereto
AR072976A1 (es) * 2008-08-08 2010-10-06 Wyeth Corp Virus de bronquitis infecciosa (ib) aislado, composicion de vacuna y metodo para preparar un virus de bronquitis infecciosa (ib) atenuado vivo
GB0911794D0 (en) * 2009-07-07 2009-08-19 Animal Health Inst Chimaeric protein
US20140141043A1 (en) * 2012-11-16 2014-05-22 Auburn University Compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus
US9764025B2 (en) * 2014-10-20 2017-09-19 Auburn University Adaptation of attenuated infectious bronchitis virus (IBV) to embryonic kidney cells and vaccine thereby produced
EP3261664A1 (en) * 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
KR20190021334A (ko) * 2016-06-16 2019-03-05 베링거잉겔하임베트메디카게엠베하 감염성 기관지염 바이러스에 대한 백신
US20190358316A1 (en) * 2017-02-06 2019-11-28 University Of Maryland, College Park Infectious bronchitis virus vaccine using newcastle disease viral vector
US10772953B2 (en) * 2017-08-09 2020-09-15 Auburn University Recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for immunizing against avian infectious bronchitis virus

Also Published As

Publication number Publication date
KR20210087058A (ko) 2021-07-09
WO2020089164A1 (en) 2020-05-07
US20200129613A1 (en) 2020-04-30
CN112996537A (zh) 2021-06-18
CO2021005066A2 (es) 2021-04-30
EA202191145A1 (ru) 2021-08-23
EP3873516A1 (en) 2021-09-08
JP2022512836A (ja) 2022-02-07
JP7206383B2 (ja) 2023-01-17
MX2021004907A (es) 2021-06-15
US20220265815A1 (en) 2022-08-25
US11224649B2 (en) 2022-01-18
US11744888B2 (en) 2023-09-05
IL282465A (en) 2021-06-30
BR112021008440A2 (pt) 2021-09-28

Similar Documents

Publication Publication Date Title
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
EA200870237A1 (ru) Последовательности пептидов и композиции
EP4223773A3 (en) Methods
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
WO2007011904A3 (en) Recombinant flu vaccines
BR112017019625A2 (pt) udp-glicosiltransferases
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
AR116876A1 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
AR100942A1 (es) Composiciones y método para el control glucémico que comprenden albiglutida
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
MX2015016382A (es) Vacunas contra el virus de la influenza y sus usos.
PE20190110A1 (es) Proteinas f de prefusion del vrs estabilizadas
PE20181176A1 (es) Composiciones biofarmaceuticas
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
BR112019003462A2 (pt) proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
UY37576A (es) Anticuerpos dirigidos a hueso
CO2019012204A2 (es) Proteínas de unión al antígeno anti-jagged1
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
CO2021005069A2 (es) Vacuna de ibv h52 con proteína espicular heteróloga